Proud mentor alert! Former WashU Internal Medicine Residency Program Neha Akkad nailed her presentation on the development and validation of a CTCL specific quality of life tool across stages & a diverse population

Looking forward to expanding this effort at other centers. WashU Dermatology Amy Musiek WashUOncology

Ben Derman I would be strongly opposed to accelerated approvals in newly diagnosed setting based on MRD-neg rate in single arm trials.

My comments at the FDA ODAC on MRD as an accelerated approval endpoint in Myeloma

Safety is the big reason this is a bad decision

NEW: results from the phase 3 ASAP trial comparing remission induction versus immediate allogeneic transplantation for patients with relapsed or poor responsive acute myeloid leukaemia did not show non-inferiority #leusm #openaccess thelancet.com/journals/lanha…

Judy Trieu, MD, MPH talking on self branding and self promotion--Image Matters.

Also, bravo👏🏼 to Forum for Women in Medicine (FWIM) and Advancing Women in Academic Medicine (AWAM) for putting together such a great program for women in medicine.
WashU Gastroenterology WUSM Department of Medicine #WomenEmpowerment

And here it is: the new The EBMT handbook

Everything about transplant and cellular therapies

For everyone everywhere

Because it is FREE🎉 #EBMT24

Kudos to all contributors including The EBMT_Trainee

👇
link.springer.com/book/10.1007/9…

Finally out…happy to propose the Marginal zone lymphoma international prognostic index: a unifying score for all MZLs in need of therapy. sciencedirect.com/science/articl…

B-cell non-Hodgkin lymphomas - The Lancet thelancet.com/journals/lance…

Proud to be a co-author with Rasha Al-Lamee Matthew Shun-Shin on a 100% Bayesian clinical trial paper that also uses our latest longitudinal ordinal modeling approach, helped by the #rstats rmsb package: thelancet.com/journals/lance… How can cardiologist Matthew Shun-Shin master all this?

Madabhushi #AACR24 Oncotype Dx is $4.6K, IbRiS is $4.60, and takes 20 minutes (not two weeks). Tissue is not preserved, and accessible worldwide. Inexpensive, fast, available. Showing independent validation SWOG S8814, KM curves reported.

At the #AACR24 #LiquidBiopsy minisymposium? Check out this study co-led by Sylvan Baca MD PhD (Hiring!) Toni Choueiri, MD & Matt Freedman showing that a single liquid biopsy assay enables the detection of four epigenomic modifications in a large multi-cancer cohort nature.com/articles/s4159…

The anticancer efficacy of CAR T cells is enhanced by overexpression of FOXO1. nature.com/articles/s4158… nature.com/articles/s4158… #NBThighlight

Interleukin-4 downregulates transcription factor BCL6 to promote memory B cell selection in germinal centers dlvr.it/T5Kg7d

🧐Interested in #SpatialOmics ?

‼️‼️Registrations are now open for our 3-day course on Spatial Omics data analysis with R/Bioconductor in May: physalia-courses.org/courses-worksh…

🚀🚀Instructors: Stefano Mangiola & Luciano Martelotto 🛠🧬💻🇦🇺

As researchers presented promising early data at the AACR annual meeting this week, there was a collective feeling of cancer vaccines turning a corner. trib.al/vvNgtIH

The Revolution Medicines #AACR24 #RASBonanza continues - now in Cancer Discovery of their CLINICAL grade RAS(ON) multiRAS inhibitor - including peer reviewed publication of the 1st clinical responses in #PancreaticCancer & other KRAS mutant tumors.
aacrjournals.org/cancerdiscover…

SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions dlvr.it/T5HbCT

In follicular lymphoma, is PFS a strong surrogate for OS? 🔊 NO!

🔑 PFS is the most commonly used surrogate for drug registration in FL

👎 PFS is *weakly* associated with OS

🤯 Only 15% of variance in OS is explained by PFS

Read more in British Journal of Haematology 👇

onlinelibrary.wiley.com/share/author/F…

🎉Finally out🎉

Methodological challenges in the development of endpoints for myelofibrosis clinical trials

The Lancet Haematology Naseema Gangat Natasha Szuber Hagop Kantarjian,MD #mpnsm

authors.elsevier.com/c/1iufd_rV3GEn…

News—
More Robust Data Should Be Required Before Drugs Fully Approved.
bit.ly/4b4ZUPN
AACR #AACR24